What is HC Wainwright’s Estimate for Alumis Q1 Earnings?

Alumis Inc. (NASDAQ:ALMS) – Stock analysts at HC Wainwright decreased their Q1 2025 earnings estimates for shares of Alumis in a research report issued to clients and investors on Thursday, March 20th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($1.29) for the quarter, down from their prior estimate of ($0.99). HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share. HC Wainwright also issued estimates for Alumis’ Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.01) EPS, Q4 2025 earnings at ($1.01) EPS and FY2025 earnings at ($4.26) EPS.

Other research analysts have also recently issued research reports about the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a research note on Thursday, March 20th. Oppenheimer started coverage on Alumis in a research note on Thursday, January 30th. They set an “outperform” rating and a $32.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $26.00.

Alumis Price Performance

NASDAQ:ALMS opened at $3.78 on Monday. Alumis has a 1-year low of $3.18 and a 1-year high of $13.53. The firm has a 50-day moving average of $5.62 and a two-hundred day moving average of $8.49.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets acquired a new stake in shares of Alumis during the 3rd quarter valued at approximately $27,000. Wells Fargo & Company MN raised its holdings in shares of Alumis by 77.1% during the fourth quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock worth $69,000 after purchasing an additional 3,823 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in shares of Alumis in the 4th quarter valued at about $79,000. MetLife Investment Management LLC bought a new stake in shares of Alumis during the 3rd quarter valued at about $89,000. Finally, Marshall Wace LLP acquired a new stake in Alumis during the fourth quarter worth about $108,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.